ACDM News Item

Recent News in Regulatory Landscape

Date: June 11, 2026

The ACDM Regulatory Considerations DMEG have kindly put together a short news piece detailing recent news across the regulatory landscape in Clinical Data Management.

Read their update here:

Exciting news in the regulatory space! ICH released ICH E6 R3 Annex 2 on June 3, 2026. According to the introduction Annex 2 supplements R3 and Annex 1 approach to applying risk proportionate approaches to trial design and conduct. Annex 2 expands on this with a focus on decentralized trials approaches, pragmatic elements and real-world data (RWD).

The ACDM DMEG on Regulatory Considerations is looking forward to reviewing Annex 2 and publishing a summary of the highlights that impact data management. But in the interim we wanted to share the document with you. You can access the document using the link below.

https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Annex%202_Guideline_Step%204_2026_0603_0.pdf

The Regulatory Considerations Expert Group provides guidance on a range of topics related to regulatory frameworks in clinical data management. This includes where to find applicable regulations, how to stay informed about new and emerging requirements, and which specific areas are relevant to data management, along with what they mean in practice. Find out more about their work here: https://acdmglobal.org/regulatory-considerations-dmeg/

Explore More News

Regulatory Considerations DMEG Shares Update on ICH E6(R3) Training Modules Available

The ICH Working Groups and The ICH Training Associates have released two new training . . .

Recent update from the regulatory landscape in clinical data management

On 22 September, MHRA published a new set of inspection dossier documents specifically for . . .

Regulatory Considerations DMEG Update – August 2026

Please read the following update from the Regulatory Considerations DMEG: July and . . .

Get to know ACDM Board Member: Santosh Karthikeyan Viswanathan

We caught up with one of ACDM’s new Board Members, Santosh Karthikeyan Viswanathan, to . . .

Guidance on Decentralized Clinical Trials to be Reviewed by the ACDM RC DMEG

Health Canada (HC) continues to publish new guidelines to support their modernization of . . .

Regulatory Considerations DMEG to Review Health Canada’s Draft Guidance

Thank you to the Regulatory Considerations DMEG for sharing this update. Health Canada . . .

Recent update from the regulatory landscape in clinical data management

Thank you to the Regulatory Considerations DMEG for sharing this update. On July 15 the . . .

Regulatory Considerations DMEG Update – June 2026

Please read the following update from the Regulatory Considerations DMEG: Regulators have . . .

FDA Announces New Initiative for Real-Time Clinical Trials

The U.S. Food and Drug Administration (FDA) has announced a new initiative to support the . . .

Get to know ACDM Board Member Jennifer Duff

We caught up with one of ACDM’s new Board Members, Jennifer Duff, to learn more about her. . . .

Recent News in Regulatory Landscape

The ACDM Regulatory Considerations DMEG have kindly put together a short news piece . . .

Real-Time Clinical Data Flow: Why the FDA’s New Pilot Validates the Data Flow Modernization Agenda

Tamer Chowdhury, on behalf of ACDM Technology DMEG. On April 28, FDA Commissioner Dr. . . .